# Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

> **NCT04387461** · PHASE2 · COMPLETED · sponsor: **CG Oncology, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Non Muscle Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** CG0070
- **BIOLOGICAL:** Pembrolizumab Injection
- **OTHER:** n-dodecyl-B-D-maltoside

## Key facts

- **NCT ID:** NCT04387461
- **Lead sponsor:** CG Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-08
- **Primary completion:** 2023-03-07
- **Final completion:** 2024-05-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387461, "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04387461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*